Biotechnology

A new drug, CS-1103, earns FDA Fast Track to combat fentanyl overdoses by binding and removing the opioid, a potential game-changer over naloxone.

A new 'dream team' of experts will guide AI development to create non-invasive tools for a deadly lung disease, aiming to replace painful procedures.

UK biotech Cytospire Therapeutics secures major funding to push its safer, more selective gamma delta T-cell engager into clinical trials for solid tumors.

UK biotech Cytospire secures a major Series A to bring its novel pan-gamma delta T cell engagers, targeting tough solid tumors, into clinical trials.

A top European fertility network is rolling out AI to select embryos, promising higher success rates but sparking debate on the future of data-driven parenthood.

Beyond its first blockbuster, CRISPR Therapeutics reveals a deep pipeline for autoimmune and liver diseases, backed by a strong Q1 balance sheet.

The biotech's blockbuster Nasdaq debut provides crucial capital for its promising pipeline, offering new hope for patients with severe bleeding conditions.

A landmark deal brings a promising, but unapproved, therapy for a rare blinding disease to French patients via a special compassionate use program.

ProBio's new Viral Vector Packaging Test promises to accelerate development and reduce risks, addressing major hurdles in bringing cell and gene therapies to market.

A major investment in natural killer cell immunotherapy aims to revolutionize treatment for Canada's most fatal women's cancer after decades of stagnation.

LANGLARA, a new Lantus biosimilar, gains FDA approval, promising more affordable diabetes care. But it faces a tough fight in a competitive market.

The new Gibco CTS DynaXS bioreactor aims to unlock scalable production, making life-saving cell therapies more accessible and affordable for patients.

A German biotech's novel in vivo CAR T platform uses DNA for durable tumor control, aiming to make advanced cancer therapy an off-the-shelf medicine.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

Valitor's VLTR-559 shows superior durability in preclinical data, potentially slashing wet AMD treatment from monthly injections to just two per year.

A landmark partnership between Propella Group and TISTR aims to unlock Thailand's hidden scientific gems, creating a pipeline for global VCs.

A devastating infant liver disorder meets a potential breakthrough. Satellite Bio's novel cell therapy just received a critical FDA nod, paving the way for trials.

An ultra-rare disease affects thousands, but few are diagnosed. Now, a new alliance of industry and advocates is racing to solve the diagnostic puzzle.

The biopharma firm gets a significant non-dilutive cash infusion, bolstering its finances to advance a promising oncology pipeline without equity dilution.

With backing from Eli Lilly, Cabaletta Bio's $150M financing will accelerate its potentially curative cell therapies for autoimmune diseases.